Abstract: Disclosed is a process for preparing a highly pure 1,1,1,2,3-pentachloropropane product, comprising 1-a) providing a reaction mixture comprising ethylene, carbon tetrachloride and a catalyst in a principal alkylation zone to produce 1,1,1,3-tetrachloropropane in the reaction mixture, and 1-b) treating the reaction mixture obtained in step 1-a) to obtain a 1,1,1,3-tetrachloropropane feedstock; 2-a) contacting the 1,1,1,3-tetrachloropropane feedstock with a catalyst in a dehydrochlorination zone to produce a reaction mixture comprising 1,1,1,3-tetrachloropropane and 1,1,3-trichloropropene, and 2-b) treating the reaction mixture obtained in step 2-a) to obtain a 1,1,3-trichloropropene feedstock; 3-a) contacting the 1,1,3-trichloropropene feedstock with chlorine in a reaction zone to produce a reaction mixture containing 1,1,1,2,3-pentachloropropane and 1,1,3-trichloropropene, the reaction zone being different from the dehydrochlorination zone, and 3-b) treating the reaction mixture obtained in step 3-a) to ob

Abstract: The present invention provides: a method for producing a fluorinated alkane represented by the formula (2): R2—F, wherein an alcohol having 3 to 5 carbon atoms is fluorinated by a fluorinating agent represented by the formula (1): R1SO2F in the absence of a solvent, and in the presence of a base selected from the group consisting of an amidine base and a phosphazene base; a method for separating and recovering an amidine base from an amidine base-sulfonate complex represented by the following formula (5); and a method for using a recovered amidine base. In the formula, R1 represents a methyl group, an ethyl group or an aromatic group, R2 represents an alkyl group having 3 to 5 carbon atoms, and n is 0 or 2.

Abstract: A process for the production of vinyl chloride comprises the step of passing a feed stream comprising ethylene dichloride (EDC) over a catalyst system comprising a dehydrochlorination catalyst and a hydrochlorination catalyst at a temperature, which may be in the range 150-350° C., sufficient to effect dehydrochlorination of the ethylene dichloride to produce vinyl chloride.

Abstract: The present invention is directed to a pyrolysis method. The method involves providing a biomass and subjecting the biomass, in a reactor operating under conditions of parasitic heat loss of less than 1% of the biomass' chemical energy content, to partial oxidation where, during steady state operation of the reactor, oxygen is provided to the reactor in sufficient quantity to achieve an equivalence ratio of 0.06 to 0.15 to release sufficient energy to support endothermic pyrolysis reactions and produce condensable organic compounds as the major portion of the pyrolysis products.

Abstract: Disclosed herein are compositions and methods of making phenolic compounds and phenolic resins. The resins include multifunctional epoxies, amino glycidyl derivatives, alkanoate derivatives, alkyl ether derivatives, and multi-functional amines prepared from hydroxymethyl derivatives of novolac resin.

Abstract: In a cross coupling reaction, in a case where a halogen atom is selected as the leaving group of the raw material compound, a harmful halogen waste forms as a by-product after the reaction, and disposal of the waste liquid is complicated and environmental burden is high. In a carbon-hydrogen activation cross coupling reaction which requires no halogen atom as the leaving group, although no halogen waste forms as a by-product, the reaction substrate is considerably restricted, and the reaction remains a limited molecular construction method. A method for producing an aromatic compound, which comprises subjecting an aromatic nitro compound and a boronic acid compound to a cross coupling reaction in the presence of a metal catalyst.

Abstract: The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol or its derivatives/chemical variants in the manufacture of a medicament for the treatment of tumors or cancers. The dihydrostilbenes can be used in the treatment or delay of progression of a cancer in a patient or used in a pharmaceutical formulation for the aforementioned purposes.

Abstract: The present invention relates to novel tertiary alcohol derivatives substituted with aryl and trifluoromethyl, and optical isomers thereof. In addition, the present invention also relates to methods for the preparation and use as enantiomer recognition agent thereof. The present invention provides pharmaceutical composition and use as therapeutically active substance thereof.

Abstract: Provided is a method for producing acetic acid, which suppresses catalyst precipitation and accumulation in an evaporator, can efficiently recycle catalysts to a reaction vessel, and can contribute to maintenance and improvement in acetic acid productivity and securing of safety operation. In the method, the evaporator has a catalyst precipitation and accumulation prevention structure: (a) structure where inclination angle ? of inside wall surface of an inverted truncated conical cylindrical connection portion is 5° to 85°; and/or (b) structure where a vortex breaker comprising a plate-like vortex breaker main body and a leg is disposed such that the vortex breaker main body covers right above the connection portion of an evaporator bottom part to a residual liquid stream recycle line, and linear velocity r of the residual liquid stream passing through a gap between the vortex breaker main body and the evaporator bottom part is larger than 10 m/h.

Abstract: The present invention describes a process for dehydrating alpha-substituted carboxylic acids in the presence of water at high pressures while avoiding by-products.

Abstract: A process for producing acetic acid while efficiently separating permanganate reducing compounds (PRC's) and methyl iodide is provided. PRC's are separated or removed from a mixed composition (3A) containing PRC's and methyl iodide by distilling the mixed composition in a distillation step (5) to form an overhead stream (5A), a side-cut stream (5B), and a lower stream (5C). In a distillation column of the distillation step (5), an extractant (e.g., water) extracting PRC's preferentially to methyl iodide is added to a concentration zone in which PRC's and methyl iodide are concentrated, and an extraction mixture falling from the concentration zone is withdrawn as the side-cut stream (5B).

Abstract: The invention relates to a process for the isolation of levulinic acid from an organic solution, comprising washing said organic solution with an alkaline aqueous stream to yield a washed organic solution; subjecting the washed organic solution to a distillation to yield a distillate and a distillation residue; and recovering levulinic acid from the distillate or the residue. This process may result in high yields of levulinic acid.

Abstract: A method of removing an aromatic carboxy-aldehyde from an aromatic acid or the corresponding anhydride includes reacting a hydroxylamine-containing compound with the aromatic carboxy-aldehyde to form a reaction mixture including the corresponding nitrone. A phthalic acid or corresponding anhydride prepared according to the method is also described herein. A method for the manufacture of a phenyl dicarboxylic acid includes oxidizing a xylene to provide a stream including the phenyl dicarboxylic acid and the corresponding carboxybenzaldehyde and toluic acid contaminants, reacting a hydroxylamine-containing compound with the carboxybenzaldehyde in the stream to form a reaction mixture including the corresponding nitrone, wherein the nitrone is water soluble, and crystallizing the phenyl dicarboxylic acid or the corresponding anhydride from water to provide the purified phenyl dicarboxylic acid or the corresponding anhydride.

Abstract: The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.

Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.

Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention provides a (meth)acrylate manufacturing method characterized in that when manufacturing a (meth) acrylate by an ester exchange reaction between an alcohol and a monofunctional (meth)acrylate using catalyst A and catalyst B together, contact treatment of the ester exchange reaction product with adsorbent C is performed. Catalyst A: One or more kinds of compounds selected from a group consisting of cyclic tertiary amines with an azabicyclo structure and salts or complexes thereof, amidine and salts or complexes thereof, compounds with a pyridine ring and salts or complexes thereof, phosphines and salts or complexes thereof, and compounds with a tertiary diamine structure and salts or complexes thereof. Catalyst B: One or more kinds of compounds selected from a group consisting of compounds comprising zinc. Adsorbent C: One or more kinds of compounds selected from a group consisting of oxides and hydroxides comprising at least one of magnesium, aluminum and silicon.

Abstract: A process for carrying out a reaction in a reaction column, said process comprising: providing a first reactant to the reaction column in the liquid phase; contacting said first reactant with an excess of a second reactant such that reaction takes place within the reaction column to form a low boiling product and a high boiling product, at least a portion of said second reactant being provided to the reaction column in the vapour phase; recovering an overhead stream from at, or near, the top of the reaction column, said overhead stream comprising unreacted second reactant and the low boiling product; and recovering a bottoms stream from at, or near, the bottom of the reaction column comprising the high boiling product; wherein at least a portion of the heat required to vaporise the second reactant provided to the reaction column in the vapour phase is provided by heat exchange in a heat exchanger with a hot stream generated within the process other than a hot stream generated within the reaction column.

Abstract: A diester of a fused ring compound of the formula (I): wherein the R1 to R6 substituents are H or ester moieties having C1 to C20 alkyl chains, but when both fused rings are aromatic and R3 and R4 are ester moieties, the alkyl chains are not C5 or C8, and polymer compositions containing the fused ring compound.

Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that may metabolize to ornithine. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

Abstract: New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.

Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: The disclosure relates to a process for preparing a fluorinated diazoalkane in which the process is a continuous process and a ?,?-difluoroalkylamine is reacted with an organic nitrite in a reactor, and in which the ?,?-difluoroalkylamine and the organic nitrite are initially charged in separate vessels, and also to the use of the process for preparing a fluoroalkyl-substituted compound.

Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: The present application relates to a novel phthalonitrile compound and a use thereof. The phthalonitrile compound has a novel structure and can exhibit excellent effects in a use known for which a phthalonitrile compound can be applied. The use of the phthalonitrile compound can be exemplified by a material or a precursor such as a phthalonitrile resin, a phthalonitrile dye, a fluorescent whitening agent, a photographic sensitizer, or an acid anhydride.

Abstract: It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.

Abstract: The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof.

Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Abstract: The invention relates to a method for producing compounds of formula (Ia), in particular to a method for producing N-[4-(cyclopropylcarbamoyl)phenylsulfonyl]-2-methoxybenzamide.

Abstract: The present invention relates to beta-naphthol ether sulfonic acids or salts thereof having the general formula (I) R—O-(AO)n—CH2—CH2—S(O)3M (I), where R, AO, n and M have the definitions stated in the claims and in the description, to mixtures thereof, to aqueous solutions and to electrolytes comprising them, to processes for preparing them and to the use of these.

Abstract: The present invention relates to a process for producing an allyl-substituted bisphenol compound including a step of subjecting a diallyl etherified bisphenol compound represented by the following general formula (I) to a thermal rearrangement reaction in the presence of a specific phosphine compound [in the formula, A represents a single bond, —SO2—, —S—, —O—, a divalent group represented by the following formula (i-1), or a divalent group represented by —CY1Y2—(Y1 and Y2 each independently represent hydrogen, a linear, branched, or cyclic alkyl group having 6 or less carbon atoms, a phenyl group, or an aralkyl group having 7 or 8 carbon atoms), B1 and B2 each independently represent a linear, branched, or cyclic alkyl group having 6 or less carbon atoms, an allyl group, a phenyl group, or an aralkyl group having 7 or 8 carbon atoms, and n1 and n2 each independently represent an integer from 0 to 2,

Abstract: A process for the preparation of methionine ?-hydroxy analogue and derivatives thereof comprising contacting one or more sugars or derivatives thereof with a metallo-silicate composition in the presence of a compound comprising sulphur and a solvent.

Abstract: The present invention provides methods of forming hydrogen sulfide. The methods include contacting a precursor compound with an unmasking agent; wherein the precursor compound comprises a hydrogen sulfide releasing moiety and a masked nucleophile; and wherein the contacting is conducted under conditions sufficient for cyclization of the precursor compound via lactone or lactam formation; thereby releasing hydrogen sulfide from the precursor compound. Hydrogen sulfide precursor compounds according to Formula I are also described, as well as methods for treating diseases and conditions using hydrogen sulfide precursors.

Abstract: Process for converting a carboxamide to a thiocarboxamide includes reacting (a) a substrate that comprises a heteroatom-containing moiety and a carboxamide moiety with (b) a dialkyl dithiophosphate and/or a salt thereof. The heteroatom-containing moiety includes a heteroatom selected from the group consisting of N, O, and S. Processes for preparing piperidine-4-thiocarboxamide are described.

Abstract: The present invention relates to 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxyderivatives of latanoprost and 15-nitrooxyderivatives of latanoprost free acid.

Abstract: The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxy derivatives of fluprostenol.

Abstract: This invention relates to a hemifumarate salt of 1-(4- 1-[(E)-cyclohexyl-3-tritluoromethy 1-benzy loxyimino ]-ethy 1)-2-ethy1-benzy l)-azetidine-3-carboxy lie acid (Compound) to pharmaceutics compositions comprising this salt, to processes for forming this salt and to its use in medical treatment, addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

Abstract: This invention provides, among other things, compounds useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus or treating a disease.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

Abstract: Pharmaceutical compositions containing a compound of formula (I) wherein the radicals denote e.g.: R1 is hydrogen or C1-C8-alkyl; R2 is hydrogen or C1-C8-alkyl; R3 is hydrogen or C1-C8-alkyl; R4 is OH; R5 is hydrogen, and a pharmaceutically acceptable cyclodextrin derivative can be used for the preparation of ophthalmic formulations.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

Abstract: A compound of the general formula (A) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, stereoisomer or mixture thereof, in which: X is independently NO2 or H; and Y is selected from H, amino, amide, ester, carboxy and its esters and amides, alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, aryl, heterocyclic or heteroaryl groups, all of which can be substituted with heteroatoms and/or side groups, and wherein any chains can be straight or branched is disclosed.

Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.

Abstract: A cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof, wherein the structural formula of the compound is as follows: An application of the compound or its pharmaceutically acceptable salts, hydrates, solvates, or prodrugs in preparing a drug for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes is provided. A drug composition includes the cyclopropyl unsaturated quinoline compound or the pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. The compound series has favorable foreground in preparing the drugs for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes.

Abstract: In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.

Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.

Abstract: The present invention relates to a novel method for preparing 5-fluoro-1H-pyrazole-4-carbonyl fluorides by halogen exchange reaction of 5-chloro-1H-pyrazole-4-carbonyl chlorides with alkali metal fluorides, using non-polar solvents.